NEW YORK (GenomeWeb News) – Clinical Data has raised gross proceeds of $47.4 million through the sale of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share.

According to a filing with the US Securities and Exchange Commission filed today, net proceeds from the offering are approximately $44.1 million. The underwriters of the offering have an option to purchase an additional 412,500 shares, which would bring total gross proceeds to $54.6 million. The offering is expected to close on Nov. 2, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.